Skip to main content

Find Clinical Trials

Home
Conditions
Pasteurellaceae Infections

Clinical trial condition

Pasteurellaceae Infections

Explore clinical trials studying Pasteurellaceae Infections. Study availability and eligibility vary by location and protocol.

159 public trials 3 recruiting studies

Refine in advanced search Browse all conditions

Pasteurellaceae Infections trial results

Completed

A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults

NCT03208101

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +36 more
Locations: Korea University Guro Hospital Seoul, South Korea

View Trial Details

Completed

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

NCT01616459

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +6 more
Locations: GSK Investigational Site Benešov, Czechia

GSK Investigational Site Děčín, Czechia

GSK Investigational Site Domažlice, Czechia

GSK Investigational Site Jindřichův Hradec, Czechia

View all 42 locations

View Trial Details

Completed

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

NCT01262872

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +6 more
Locations: GSK Investigational Site Banjul, The Gambia

View Trial Details

Completed

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

NCT01204658

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +6 more
Locations: GSK Investigational Site Benešov, Czechia

GSK Investigational Site Brno, Czechia

GSK Investigational Site Děčín, Czechia

GSK Investigational Site Jindřichův Hradec, Czechia

View all 24 locations

View Trial Details

Completed

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

NCT03931239

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +25 more
Locations: Hung Yen, Kim Dong Hung Yen, Vietnam

View Trial Details

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

NCT01341639

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

NCT01480258

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details

Completed

A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years

NCT00625118

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +3 more
Locations: Health Protection Agency Gloucester, United Kingdom

Health Protection Agency London, United Kingdom

View Trial Details

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

NCT01337167

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details

Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

NCT01340937

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details